Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.

Mydecine announces research agreement with a leading pharmacology research institution.

PharmaDrug adds depth to its board with new Director who has a wealth of healthcare and addiction-therapy experience.

MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.

High-potency marijuana concentrates on today’s legal markets can contain upwards of 90 percent THC, so one might reasonably expect them to pack a greater psychoactive punch than typical flower, which tops out around 30 percent.

ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.

Field Trip Psychedelics is planning to go public via a “three-cornered” RTO.

Field Trip Psychedelics has just announced a letter of intent to go public via RTO.

New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company’s Advisory Board.